BRIEF published on 03/20/2026 at 13:05, 7 days ago ReproNovo Appoints Mark Altmeyer as Chairman of the Board Biopharmaceutical Fertility Leadership ReproNovo Mark Altmeyer
BRIEF published on 03/20/2026 at 13:05, 7 days ago ReproNovo nomme Mark Altmeyer président du conseil d'administration Biopharmaceutique Direction ReproNovo Mark Altmeyer Fécondité
PRESS RELEASE published on 03/20/2026 at 13:00, 7 days ago REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD ReproNovo appoints Mark Altmeyer as Chairman of the Board. Altmeyer brings 35+ years of biopharma leadership experience across multiple therapeutic areas Chairman Fertility Biopharma ReproNovo Mark Altmeyer
BRIEF published on 09/30/2025 at 07:05, 5 months 27 days ago ReproNovo Gains Approval for RPN-001 Clinical Trial in China Clinical Trial China Approval ReproNovo Reproductive Medicine RPN-001
BRIEF published on 09/30/2025 at 07:05, 5 months 27 days ago ReproNovo obtient l'approbation pour l'essai clinique RPN-001 en Chine Essai Clinique ReproNovo RPN-001 Approbation De La Chine Médecine De La Reproduction
PRESS RELEASE published on 09/30/2025 at 07:00, 5 months 27 days ago ReproNovo Announces Clinical Trial Approval Notice for RPN-001 in China ReproNovo receives approval for RPN-001 Phase 1 trial in China from NMPA, a key step in global development for male infertility treatment. Company expanding clinical programs in the U.S. and China China Male Infertility Clinical Trial ReproNovo RPN-001
BRIEF published on 07/01/2025 at 07:05, 8 months 26 days ago ReproNovo Initiates Phase 2 Trial for Male Infertility Drug in the U.S. Male Infertility Phase 2 Trial ReproNovo RPN-001 Low Testosterone
BRIEF published on 07/01/2025 at 07:05, 8 months 26 days ago ReproNovo lance un essai de phase 2 pour un médicament contre l'infertilité masculine aux États-Unis Essai De Phase 2 ReproNovo RPN-001 Infertilité Masculine Faible Taux De Testostérone
PRESS RELEASE published on 07/01/2025 at 07:00, 8 months 26 days ago REPRONOVO ANNOUNCES FIRST PARTICIPANT INCLUDED IN U.S. PHASE 2 TRIAL OF RPN-001 FOR MALE INFERTILITY ReproNovo announces first participant in U.S. Phase 2 trial of RPN-001 for male infertility, aiming to develop oral therapy for low testosterone men with impaired semen quality Male Infertility Phase 2 Trial ReproNovo RPN-001 Aromatase Inhibitor
BRIEF published on 05/21/2025 at 07:05, 10 months 6 days ago ReproNovo Secures $65 Million for Phase 2 Trials in Reproductive Health Innovation Clinical Trials Series A Financing Reproductive Health ReproNovo
Published on 03/27/2026 at 12:30, 1 hour 8 minutes ago Pasinex Closes First Tranche of Over-Subscribed Non-Brokered Private Placement
Published on 03/27/2026 at 12:00, 1 hour 38 minutes ago Temas Appoints Scientific Advisory Board to Accelerate RCL Commercialisation and Global Development
Published on 03/27/2026 at 11:00, 2 hours 38 minutes ago RE Royalties Announces Strategic Review to Evaluate Path for Long-Term Value Creation
Published on 03/27/2026 at 09:30, 4 hours 8 minutes ago Amap Street Stars Launches Macao Authentic Delicacies Ranking to Drive Cultural-Tourism Innovation in the Greater Bay Area
Published on 03/27/2026 at 13:00, 37 minutes ago NR21: Mise à disposition du Rapport financier annuel 2025
Published on 03/27/2026 at 11:45, 1 hour 52 minutes ago Second National Showcase of Outstanding Works from China’s Rare Operatic Genres Held
Published on 03/27/2026 at 11:45, 1 hour 52 minutes ago Deuxième édition du Festival des chefs-d’œuvre des genres rares de l’opéra chinois Un événement dédié aux opéras traditionnels en voie de disparition
Published on 03/27/2026 at 11:40, 1 hour 57 minutes ago Disposal of shares in Pension Insurance Corporation Group Limited
Published on 03/27/2026 at 07:00, 6 hours 38 minutes ago WEB SA - CONVOCATION ASSEMBLEE GENERALE ORDINAIRE EXERCICE 2025 - 28/04/2026
Published on 03/26/2026 at 18:17, 19 hours 21 minutes ago Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 19 hours 21 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 19 hours 38 minutes ago Arrêté des comptes au 31 décembre 2025 et perspectives 2026
